Publication | Open Access

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Herceptin AdjuvantBreast OncologyOncologyImmunologyAdjuvant ChemotherapyBreast CancerCancer TreatmentMedicineRadiation OncologyFinal Analysis